Gina Ogilvie is a senior scientist at BCCDC. She is also a senior advisor at BC Women’s Hospital Health Centre, the assistant director of the Women’s Health Research Institute, and a professor in the UBC School of Population & Public Health.
Dr. Ogilvie's clinical and research work focuses on the public health and clinical aspects of reproductive health, human papillomavirus infection and vaccines, HIV in women and care for marginalized populations, and other sexually transmitted infections.
She has received several recognitions and awards, including the American Sexually Transmitted Diseases Association (ASTRA) Achievement Award (2021 and 2020); UBC Killam Faculty Research Prize (2020); Michael S. O'Malley Alumni Award for Publication Excellence (2019); YWCA Woman of Distinction (2018); President's Award, Children and Women's Health Centre of BC (2018); Options for Sexual health Sexual Health Champion of the Year (2018); Provincial Health Officer's Award for Excellence in Public health (2015); Researcher of the Year, College of Family Physicians of Canada (2014); YWCA Women of Distinction Nominee (2014); and Distinguished Achievement in Research, Faculty of Medicine, UBC (2014).
She is also a Tier 1 Canada Research Chair at Global Control of HPV Related Disease and Cancer. She is principal investigator on over 10 million dollars in research grants and has received funding from PHAC, CIHR, Michael Smith Foundation for Health Research, Canadian Foundation for Innovation and private foundations.
Dr. Ogilvie obtained her medical degree and family practice certification at McMaster University, followed by a fellowship in population health at McMaster University. She completed her master of science (MSc) in clinical epidemiology at UBC, focusing on the care of HIV-positive women, and her doctor of public health (DrPH) in HPV primary screening at the University of North Carolina at the Gillings School of Global Public Health.
She has published over 150 peer reviewed manuscripts and provides advice and consultation to national and international institutions, including the Canadian Partnership Against Cancer, Public Health Agency of Canada, the World Health Organization (WHO), and Ministries of Health on STI, HIV and HPV vaccine policy and programming.
